InvestorsHub Logo
Followers 73
Posts 6214
Boards Moderated 0
Alias Born 05/01/2011

Re: Atom0aks post# 208898

Wednesday, 08/14/2019 4:21:28 PM

Wednesday, August 14, 2019 4:21:28 PM

Post# of 426086
No, we're outside the guidelines. The guidelines are about getting stuff done within the specified review period, which in this case was a Priority Review. They just blew all that up with the AdCom decision, which normally would have been made no later than the mid-cycle review meeting.

We are in largely uncharted territory here, and the history between the FDA and AMRN is unique. The guidelines you've been referencing are helpful in terms of expectations, but the possible range of explanations behind all of this has now been blown wide open.

Anybody who says they are sure what is going behind the scenes right now, in terms of either content or timeframe, is full of it.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News